Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lexapro in Acute Treatment of Severe Depression
NCT01814085Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of escitalopram in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants With Remission Based on Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Feb 2010; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01814085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01814085.